Unfortunately, legal restrictions prevent us from allowing you access to this part of the website.
If you have any questions, please call the Vitrafy Offer Information Line on 02 7208 8033 (within Australia) or +61 2 7208 8033 (outside Australia) 8.30am to 5.00pm (AEDT) on Monday to Friday during the Offer Period (excluding public holidays).
Due to legal restrictions, access to this website is only available to residents of Australia from within Australia. In order to access this website, you must provide the State or Territory and Postcode for your primary residential address within Australia.
By proceeding you confirm that you are a resident of Australia accessing this website from within Australia and you represent, warrant and agree that:
- you are not a "U.S. person" (as defined in Regulation S under the United States Securities Act of 1933) nor are you acting for the account or benefit of a U.S. person;
- you will not make a copy of the Prospectus available to, or distribute a copy of the Prospectus to, any such "U.S. person" or to any person in any other place outside Australia in which, or to any other person to whom, it would be unlawful to do so (Ineligible Persons);
- you are not acting as a nominee for, or otherwise for the account or benefit of, any Ineligible Persons; and
- the State and Territory and postcode provided by you for your primary residence in Australia is true and accurate.
Vitrafy Life Sciences Limited (ACN 622 720 254) (Company) has lodged a prospectus dated 6 November 2024 (Prospectus) with the Australian Securities and Investments Commission (ASIC) in relation to an offer of fully paid ordinary shares (Shares) in the Company (Offer), a copy of which is available on this website.
None of ASIC, ASX Limited (ABN 98 008 624 691) or the securities exchange that it operates, as the context requires (ASX) or their respective officers takes any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.
The Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares or the Offer, or to otherwise permit a public offering of Shares, in any jurisdiction outside Australia.
The distribution of the Prospectus outside Australia (including electronically) may be restricted by law. If you come into possession of the Prospectus outside Australia, you should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. The return of a duly completed Application Form or making of the application payment for Shares by BPAY® will be taken by the Company to constitute a representation and a warranty made by the applicant to the Company that there has been no breach of such laws and that all necessary approvals and consents have been obtained.
The Shares have not been, or will not be, registered under the United States Securities Act of 1933, as amended (U.S. Securities Act) or any U.S. state securities laws and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
You should ensure that any copy of the Prospectus you view or print is complete. To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading Prospectus from this website, including, but not limited to, data corruption on download.
This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.
On 30 October 2024, Vitrafy Life Sciences Limited (ACN 622 720 254) (Company) announced an offer of fully paid ordinary shares (Shares) in the Company (Offer).
Capitalised terms used in this site have the meanings found in the Prospectus.
The Offer comprises a Broker Firm Offer, a Priority Offer and an Institutional Offer.
The Broker Firm Offer is open only to Australian resident retail clients of Brokers who have received a firm allocation of Shares from their Broker.
The Priority Offer is open only to investors who have received an invitation to participate in the Priority Offer from the Company and who have a registered address in Australia and are not located in the United States.
The Institutional Offer consisted of an invitation to bid for Shares made to Institutional Investors in Australia and certain other eligible jurisdictions.
The Offer is expected to raise $35 million based on the Offer Price of $1.84.
The Shares have not been, or will not be, registered under the U.S. Securities Act or any U.S. state securities laws and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
Further Information
If you have any questions, you should seek professional guidance from your solicitor, stockbroker, accountant or other independent and qualified professional adviser or call the Vitrafy Offer Information Line on 02 7208 8033 (within Australia) or +61 2 7208 8033 (outside Australia) 8.30am to 5.00pm (AEDT) on Monday to Friday during the Offer Period (excluding public holidays).
